AstraZeneca plc (AZN) Given “Hold” Rating at Liberum Capital
AstraZeneca plc (LON:AZN)‘s stock had its “hold” rating reiterated by equities research analysts at Liberum Capital in a research report issued on Tuesday. They currently have a GBX 5,200 ($67.88) price objective on the biopharmaceutical company’s stock. Liberum Capital’s target price indicates a potential upside of 2.24% from the company’s previous close.
Several other equities analysts also recently commented on the stock. Goldman Sachs Group Inc. set a GBX 4,000 ($52.21) target price on shares of AstraZeneca plc and gave the stock a “sell” rating in a research report on Tuesday, October 4th. JPMorgan Chase & Co. restated a “neutral” rating and set a GBX 4,900 ($63.96) price target on shares of AstraZeneca plc in a report on Monday, October 3rd. BNP Paribas restated a “neutral” rating and set a GBX 5,200 ($67.88) price target on shares of AstraZeneca plc in a report on Friday, September 30th. Shore Capital reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Wednesday, September 28th. Finally, Deutsche Bank AG reiterated a “buy” rating and issued a GBX 5,800 ($75.71) target price on shares of AstraZeneca plc in a research note on Wednesday, September 28th. Five investment analysts have rated the stock with a sell rating, fourteen have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of GBX 4,937.91 ($64.46).
AstraZeneca plc (LON:AZN) traded up 1.19% on Tuesday, hitting GBX 5086.00. The company had a trading volume of 3,384,720 shares. AstraZeneca plc has a 12-month low of GBX 3,680.00 and a 12-month high of GBX 5,505.00. The firm’s 50 day moving average price is GBX 5,005.11 and its 200 day moving average price is GBX 4,435.88. The stock’s market cap is GBX 64.34 billion.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/09/astrazeneca-plc-azn-given-hold-rating-at-liberum-capital-2.html
The firm also recently declared a dividend, which was paid on Monday, September 12th. Shareholders of record on Thursday, August 11th were paid a GBX 68.70 ($0.90) dividend. The ex-dividend date was Thursday, August 11th. This represents a yield of 1.37%.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.